Latest news with #ThermoFisher
The Hindu
2 days ago
- Health
- The Hindu
Research consumables supply center inaugurated at AIC-CCMB in Hyderabad; it cuts waiting time to get chemical agents
A special 'supply center' providing accessibility to essential research consumables for the life science research community in and around the (AIC-CCMB) Atal Incubation Centre-Centre for Cellular and Molecular Biology campus at Uppal in Hyderabad was inaugurated on Wednesday (June 18, 2025). CSIR-CCMB Director Vinay Kumar Nandicoori dedicated the centre set up by 'Thermo Fisher Scientific' to the researchers in the area including those working at Centre for DNA Fingerprinting & Diagnostics (CDFD), National Institute of Nutrition (NIN) and others, in the presence of AIC-CCMB CEO N. Madhusudana Rao. Steady supply of chemical agents Dr. Kumar said the supply centre promises to reduce the usual time lags in getting the necessary chemical agents like enzymes for research purposes, as steady supply will now be available. 'It will be good for the entire eco-system as procurements otherwise could be cumbersome,' he said. Thermo Fisher's director Jayabharath Reddy said they are committed to support scientific innovation and the new supply center will enable start ups and researchers at CCMB and surrounding institutions to gain access to critical research consumables. 'Specialised consumables have always been a challenge for researchers, sometimes losing months in the process of ordering to delivering. Our centre will be putting essential materials right on campus, enabling faster scientific breakthroughs,' he said The new centre is located adjacent to the company's Centre for Innovation (CFI) established at the AIC-CCMB. The CFI was set up for fostering collaborations and advancing scientific breakthroughs in life sciences. Earlier, AIC-CCMB and Thermo Fisher are also holding a three-day workshop on 'Cell Health Analysis' to enhance technical skills of the researchers in cell based assays used in biomedical research and drug discovery. 'Cell analysis is crucial in developing therapies for cancer and other diseases. This workshop gives researchers hands-on exposure to advanced tools,' said Dr. Rao.
Forbes
3 days ago
- Business
- Forbes
Illumina's New CIO Brings R&D Mindset As AI Transforms Genomics
Illumina this month named Mark Field as its next Chief Information Officer, adding a veteran technology and R&D executive to its leadership team as the DNA sequencing giant navigates the next wave of AI and innovation in genomics. Field, who started earlier this month, is based in San Diego and reports to CEO Jacob Thaysen. He succeeds Carissa Rollins, who retired in April. With a three-decade career in enterprise IT and life sciences, Field brings a blend of corporate technology and scientific R&D experience to the role. Illumina CIO Mark Field He began his career at Oracle in 1995, gaining early insight into the internet's disruptive potential. It's a shift he sees mirrored today with the rise of AI and breakthroughs in personalized medicine. 'For the genomic age, it feels just like 1995,' Field said in an interview. Following his time at Oracle, Field led technology at Life Technologies, a life sciences company later acquired by Thermo Fisher Scientific. He was CTO at Thermo Fisher before joining Insulet Corporation, which develops medical devices for people with diabetes and other conditions. Each role reinforced his interest in how digital tools and data can accelerate scientific discovery and directly improve health outcomes, he said. Over the past few weeks, Field has been meeting teams and working to understand the ins and outs of Illumina's operations as he develops a roadmap for the future. 'My goal is to be the best partner and deliver value to the various businesses,' he said. Field says his past experience leading R&D functions in addition to corporate IT makes him well equipped to be a strong partner with that organization at Illumina. R&D is "a completely different way to perceive the world, about getting out in front, having the best product,' he said. While it's a different mindset than the one usually held by IT, technology, data and software are key to progress across both functions. Headquartered in San Diego, Illumina sells genetic sequencing products and services to medical researchers and other customers around the world. Its products are used in applications across life sciences, oncology, reproductive health, agriculture, among other segments. Illumina reported $4.3 billion in revenue for fiscal year 2024. In its most recent earnings report, the company lowered its full-year guidance and announced a $100 million cost reduction program amid ongoing geopolitical and tariff-related impacts, including a ban on imports of Illumina's products in China. Even as the company grapples with near-term headwinds, Field remains optimistic about its long-term trajectory as innovation in science and technology continues to accelerate. 'I'm more thrilled today than I was yesterday, and more thrilled yesterday than I was when I started,' he said. 'I knew it was a great company, but its potential is what's truly exciting me now.'
Globe and Mail
4 days ago
- Business
- Globe and Mail
Microcarriers Market to Hit USD 3.05 Billion by 2029 with 8.0% CAGR
"Key players in the microcarriers market include Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Sartorius AG (Germany), Corning Incorporated (US), FUJIFILM Holdings Corporation (Japan), BD (US), Eppendorf SE (Germany), Lonza (Switzerland)" Browse 761 market data Tables and 57 Figures spread through 557 Pages and in-depth TOC on "Microcarriers Market by Product (Equipment (Single Use Bioreactor, SSB, Cell Counter, Filtration), Consumables (Media, Reagent), Beads (Natural (Collagen), Synthetic (Polystyrene)), Application (Vaccine, CGT, Stem Cells) - Global Forecast to 2029 The global Microcarriers market, valued at US$2.03 billion in 2023, is forecasted to grow at a robust CAGR of 8.0%, reaching US$2.08 billion in 2024 and an impressive US$3.05 billion by 2029. Market growth is attributed to rising investments in cell & gene therapy research, growing preference for single-use technologies, and increasing R&D spending for biopharmaceutical production. However, the high cost of cell biology research and limitations in high-density cell culture production are expected to hinder the market growth over the forecast period. Download PDF Brochure: Browse in-depth TOC on " Microcarriers Market" 761 - Tables 57 - Figures 557 - Pages Based on product, the microcarriers market is segmented into consumables and equipment. The consumables segment accounted for the largest share of the microcarriers market. The large share of the consumables segment is attributed to the repeated purchase and requirement in bulk quantities of sera, media, and reagents for various microcarrier cell culture applications. Additionally, increasing production and development of advanced biopharmaceuticals is driving the growth of the segment in microcarriers market. Among application segment, the microcarriers market is segmented into tissue engineering and regenerative medicine, biopharmaceutical production, and other applications. The biopharmaceutical production segment accounted for the largest share of the microcarriers market. The large share of the biopharmaceutical production segment can be attributed to the commercial expansion of major pharmaceutical companies, growing regulatory approvals for cell culture-based vaccines, and increasing demand for monoclonal antibodies (mAbs). Among end user segment, the microcarriers market is segmented into pharmaceutical & biotechnology companies, academic and research institutes, contract research organizations & contract manufacturing organizations, and cell banks. The pharmaceutical & biotechnology companies segment accounted for the largest share of the microcarriers market. Rising awareness about the benefits of cell-based vaccines, growing regulatory approvals for cell-based vaccines, and a focus on commercial expansion are the major factors driving the growth of this segment. The microcarriers market is segmented by region into six key areas, namely North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2023, North America dominated the market followed by Europe at second position and Asia Pacific was at third position. The majority share of the market in North America. The key factors driving the growth of the market in North America include increasing demand for cell-based therapies, strong government support for stem cell research, and the presence of a well-established pharmaceutical industry that is likely to drive the growth of the market. The market in Canada is likely to grow in the coming years due to several government initiatives and the intensification of genomics R&D through the Genomic Applications Partnership Program (GAPP) in the country. In addition, the US accounted for the largest market share in the North American microcarriers market. Major share of the country is determined by factors like well-established pharmaceutical and biotechnology sector, cell therapy and biologics, and regulatory vaccine approvals. Increasing incidences of diseases like cancer along with high funding for the life sciences research are also contributing to the major share of the country. For example, According to the National Cancer Institute, there were nearly 2 million people who were suffering from US Cancer cases in 2023. The current treatment options will cater to the unmet demands if cell-based therapies are employed. Since microcarrier culture technology is used in the R&D and production of vaccines and antibiotics, it is likely that these factors will create a large number of opportunities for the growth of the microcarriers market. Europe is the second largest market after North America. The availability of government funding, growth in the biotechnology and pharmaceutical sectors, and the rise in the number of conferences, symposia, seminars, trade fairs, annual events, and workshops being organized in Europe that focus on creating awareness about microcarriers are expected to drive the growth of the market in the region. These factors help increase awareness about current technological advancements and aid in the discussion of various challenges and opportunities prevailing in the industry. Such events also offer market players the opportunity to showcase their products and communicate with stakeholders while helping scientists and researchers to exchange experiences. According to the Alliance for Regenerative Medicine (ARM), a global advocate for regenerative and advanced therapies, out of 843 regenerative medicine companies globally, Europe houses 234. Moreover, In 2023, the Asia Pacific is third largest market for microcarriers. This surge in the regional market is attributed to various factors such as government backing for cell-based vaccine production and therapies, expansion initiatives by key market players in emerging Asian economies, heightened vaccine manufacturing capacities of major companies, increased research and development investments by biotechnology and pharmaceutical firms, collaborative ventures in bioprocessing, a growing elderly population, amplified focus on regenerative medicine research, and the upsurge in preclinical/clinical research particularly in China and India. Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and Danaher Corporation (US) holding the significant global market share and the global microcarriers market is highly cosolidated. Thermo Fisher Scientific Inc. (US) Thermo Fisher Scientific (US) is a leading player in the microcarriers market. The company has strong brand image, robust product portfolio, and product development focus. The company offers its products through well-established brands such as Gibco, Nunc, Countess, Dynabeads, and HyPerforma. The company focuses on product launches, expansion, and acquisition to strengthen the position in the market. For example, in September 2023, the company introduced Gibco CTS Detachable Dynabeads, a groundbreaking platform with an innovative active-release mechanism designed for clinical and commercial cell therapy manufacturing. Merck KGaA (Germany) Merck KGaA is a leading science and technology company with a strong global presence in more than 120 countries. The company has a portfolio of more than 300,000 life science products that support a broad customer base. Merck has been a prominent player in the life sciences industry, offering various products and services to support researchers and biomanufacturers. The company has a comprehensive portfolio that includes cell culture media, reagents, and other essential tools for bioprocessing. Merck majorly focuses on expansions in key geographies to increase its customer base. In June 2023, Merck KGaA expanded its reagent manufacturing facility in Nantong, China with an investment of about USD 76.5 million. Danaher Corporation (US) Danaher Corporation is one of the leading companies in the microcarriers market, attributed to a strong product portfolio, recent acquisitions, and partnerships. Danaher Corporation (Cytiva) (US) offers a wide range of products, including microcarriers, bioreactors, media, and reagents, which greatly expanded Danaher's position and offerings in the microcarriers market. The Pall Corporation subsidiary is also active in this market and offers single-use and stainless-steel bioreactors and filtration equipment. In May 2023, Cytiva and the life sciences business of Pall Corporation completed their integration and are now united as one business under the Cytiva brand. In October 2023, Cytiva opened a new manufacturing facility in Pune, India, which will double its manufacturing capacity in the country. The facility will produce bioprocessing equipment, including tangential flow, virus filtration, and inactivation systems, to support the Indian biopharmaceutical industry. For more information, Inquire Now!
Yahoo
4 days ago
- Business
- Yahoo
Ethris and Thermo Fisher partner on mRNA solutions
Ethris has entered a strategic partnership with Thermo Fisher Scientific to provide a completely integrated messenger ribonucleic acid (mRNA) solution to biopharmaceutical developers. The partnership aims to accelerate the progression of candidate mRNA medicines from research to clinical proof-of-concept. It will combine Ethris' advanced technology platforms with Thermo Fisher's good manufacturing practice-compliant manufacturing capabilities. Ethris CEO Carsten Rudolph stated: 'Thermo Fisher Scientific has a long-standing track record of supporting the development of advanced therapies. 'By combining our clinically validated mRNA platforms with Thermo Fisher's manufacturing expertise, we are creating a powerful offering for biopharma partners. This collaboration addresses the increasing demand for scaleable, high-quality mRNA technologies and enables us to serve a broader set of collaborators worldwide.' The collaboration will expand worldwide access to Ethris' suite of mRNA technologies, including its stabilised non-immunogenic mRNA (SNIM RNA). SNIM RNAs are non-immunogenic and can therefore be administered repeatedly, resulting in sustained production of proteins that are therapeutically active within the human body. These platforms are designed for safe drug production while allowing scaleable manufacturing processes. Ethris' platform technologies have shown favourable results in Phase I trials for ETH47, a candidate targeting asthma exacerbations through nasal administration. The trial data indicated dose-dependent protein production at the site without systemic bioavailability. Thermo Fisher scientific large molecule drug substance vice-president and general manager Ben Castro stated: 'Thermo Fisher is committed to supporting the rapid translation of breakthrough therapies into clinical application. 'By partnering with Ethris, we are expanding our services to include cutting-edge mRNA manufacturing, empowering our customers to bring life-changing treatments to patients faster and more efficiently.' "Ethris and Thermo Fisher partner on mRNA solutions" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Associated Press
4 days ago
- Business
- Associated Press
Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific's Accelerator™ Drug Development 360° CDMO and CRO Solutions
WALTHAM, Mass.--(BUSINESS WIRE)--Jun 16, 2025-- Thermo Fisher Scientific Inc., the world leader in serving science, today announced the findings of new research by the Tufts Center for the Study of Drug Development (CSDD) demonstrating the benefits of the company's Accelerator™ Drug Development 360° CDMO and CRO solutions in helping biotech and biopharma companies speed life-changing medicines to patients. 1 The findings show Thermo Fisher's integrated services can potentially reduce drug development timelines by up to nearly three years, representing significant time savings on the average 10 to 15 years it takes to commercialize a new drug. Streamlining drug development is crucial for biotech and biopharma companies facing high development costs, regulatory complexity and the urgent need to bring safe, new medicines to market more quickly. Drug developers traditionally have relied on multiple supplier partners for bioprocessing, clinical development, clinical supply and manufacturing solutions; however, this decentralized approach leads to inefficiency, miscommunication and delay. Each month of delay in a Phase III clinical trial can result in up to $8 million in lost revenue resulting from shortened market exclusivity and deferred market entry. 2 The Tufts CSDD study demonstrates that working with an integrated partner to provide contract development and manufacturing organization (CDMO) and clinical research organization (CRO) solutions can help speed and streamline the complex journey of drug development. Accelerator™ Drug Development provides a customizable suite of manufacturing, clinical research and clinical supply chain services at every stage of development. To date, more than 120 biotech and biopharma companies have worked with Thermo Fisher across its integrated CDMO and CRO solutions on more than 350 protocols across therapeutic areas, small molecule, large molecule and advanced therapies. 'This new study highlights the opportunity to deliver safe new medicines to patients significantly faster,' said Mike Shafer, executive vice president and president, Biopharma Services, Thermo Fisher Scientific. 'Through Accelerator Drug Development, we are well positioned to bring customizable, end-to-end solutions and world-leading expertise to our customers, and we're proud of the capabilities we've built to meet customer and patient needs.' The Tufts CSDD study reported that using integrated services from Phase I through Phase III can reduce drug development times by up to 34 months. Researchers also found that integrated CRO/CDMO services can generate up to $63 million in net financial benefits for drug sponsors, a return on investment of up to 113 times the initial investment. In considering multiple scenarios across phases of drug development and different levels of investment in integrated services, researchers found demonstrable time savings and ROI across the board, reflecting the benefits of integration, such as cross-functional program coordination, collaboration, oversight, planning and communication. 'This study,' the authors wrote, 'demonstrates that integration of services across development and manufacturing functions can yield substantial benefits to drug sponsors in the form of shorter clinical development durations. The findings from this study provide a compelling case for drug sponsors to consider single-vendor integrated CDMO and CRO solutions as a means of addressing operational inefficiencies.' The study's lead author, Joseph DiMasi, Ph.D., director of economic analysis and research associate professor, Tufts University, said, 'The cost of developing new drugs is exacerbated by operational inefficiencies from the siloing of clinical research, drug manufacturing and supply chain functions. Our findings underscore the strategic importance of integrated services as a driver of value. Drug sponsors considering this approach should consider the degree of integration that would drive the most value for their programs. Our study reveals that while fully integrated service provision yields the greatest financial benefit, even partial integration offers significant value, especially for the later phases of clinical development.' To learn more, please visit Thermo Fisher Scientific's website. Additionally, Thermo Fisher will showcase its latest innovative and flexible solutions in support of biotechnology and biopharmaceutical companies at every stage of their drug development journey during the 2025 BIO International Convention, June 16-19 (booth #2953). Leaders from across the organization will also participate in a series of panel discussions that will highlight industry trends, strategies for sustainability and the value of collaboration to bring medicines to market faster. 1 The research was supported in part by a grant from Thermo Fisher Scientific to the Tufts Center for the Study of Drug Development. Tufts CSDD maintains a strong reputation for scholarly and objective insights drawn from hard evidence. The results of all research conducted by Tufts CSDD remain independent and are published in peer-reviewed and trade journals. The study, which researchers believe to be the first of its kind, modeled the net financial benefit of integrated CDMO-CRO services Thermo Fisher provided to customers in recent years using a risk-adjusted, discounted cash flow analysis (also known as an expected net present value analysis). While the study focused on oncology drug development scenarios, the findings may have applications more broadly across other therapeutic areas. 2 Rubio-Herrero, Javier, Anh Ninh, and Michael Lefew. 2023. 'Improving the Performance of Supply Chains in Clinical Trials with Delays: An Optimization Approach to Determining the Number of Recruitment Sites.' Annals of Operations Research. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit View source version on CONTACT: Media Contact Information: Ned Glascock E-mail:[email protected] Website: Morton E-mail:[email protected] KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY SOURCE: Thermo Fisher Copyright Business Wire 2025. PUB: 06/16/2025 08:15 AM/DISC: 06/16/2025 08:14 AM
